CL2018002930A1 - (+)-azasetron para uso en el tratamiento de desórdenes de oído. - Google Patents

(+)-azasetron para uso en el tratamiento de desórdenes de oído.

Info

Publication number
CL2018002930A1
CL2018002930A1 CL2018002930A CL2018002930A CL2018002930A1 CL 2018002930 A1 CL2018002930 A1 CL 2018002930A1 CL 2018002930 A CL2018002930 A CL 2018002930A CL 2018002930 A CL2018002930 A CL 2018002930A CL 2018002930 A1 CL2018002930 A1 CL 2018002930A1
Authority
CL
Chile
Prior art keywords
azasetron
treatment
ear disorders
disorders
ear
Prior art date
Application number
CL2018002930A
Other languages
English (en)
Spanish (es)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Publication of CL2018002930A1 publication Critical patent/CL2018002930A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2018002930A 2016-04-14 2018-10-12 (+)-azasetron para uso en el tratamiento de desórdenes de oído. CL2018002930A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19

Publications (1)

Publication Number Publication Date
CL2018002930A1 true CL2018002930A1 (es) 2019-02-15

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002930A CL2018002930A1 (es) 2016-04-14 2018-10-12 (+)-azasetron para uso en el tratamiento de desórdenes de oído.

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
JP2015511242A (ja) 2012-02-23 2015-04-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Also Published As

Publication number Publication date
DK3442537T3 (da) 2024-03-25
EP4335508A3 (en) 2024-07-10
US20230226071A1 (en) 2023-07-20
NZ747201A (en) 2023-02-24
JP7158723B2 (ja) 2022-10-24
US20190083503A1 (en) 2019-03-21
JP2019513780A (ja) 2019-05-30
EP4335508A2 (en) 2024-03-13
FI3442537T3 (fi) 2024-04-04
IL262305B (en) 2022-03-01
HUE066000T2 (hu) 2024-06-28
US11612605B2 (en) 2023-03-28
IL262305A (en) 2018-11-29
HRP20240453T1 (hr) 2024-06-21
MX2018012587A (es) 2019-03-07
AU2023202897B2 (en) 2025-01-30
ES2975016T3 (es) 2024-07-02
SI3442537T1 (sl) 2024-05-31
CN109310698B (zh) 2021-12-24
MX384045B (es) 2025-03-14
PL3442537T3 (pl) 2024-07-15
ZA201806894B (en) 2023-03-29
RS65379B1 (sr) 2024-04-30
AU2023202897A1 (en) 2023-05-25
CN109310698A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
MX2019009443A (es) Metodos para tratar la influenza.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
DOP2017000111A (es) Inhibidor de cinasa aurora a
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX378273B (es) Compuestos activos hacia bromodominios.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CL2017000050A1 (es) Terapia de combinación para el cáncer
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
AR103680A1 (es) Inhibidores selectivos de bace1
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2019014024A (es) Tratamiento de los trastornos depresivos.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
LT3687567T (lt) Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
MX392383B (es) Metodos para tratar afecciones oculares.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases